We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




British Genomic Study Finds Fifteen New Breast Cancer Loci

By LabMedica International staff writers
Posted on 22 Mar 2015
Print article
British genomic and cancer researchers have identified 15 previously unknown loci associated with the risk of developing breast cancer.

Approximately one in every eight women in the United Kingdom will develop breast cancer at some stage in their lives, and about 5% of these women carry genetic variations that double their risk of developing breast cancer. A much smaller group comprising about 0.7% of women have genetic variations that make them three times more likely to develop the disease. The purpose of this study was to find genetic markers that can help identify women at high-risk and lead to improved cancer screening and prevention.

Investigators at the University of Cambridge (United Kingdom) and colleagues in the Breast Cancer Association Consortium, part of the Collaborative Oncological Gene-environment Study, performed a meta-analysis of 11 GWAS (genome-wide association study), comprising 15,748 breast cancer cases and 18,084 controls together with 46,785 cases and 42,892 controls from 41 studies genotyped on a 211,155-marker custom array (iCOGS). Analyses were restricted to women of European ancestry.

The investigators generated genotypes for more than 11 million SNPs (single nucleotide polymorphisms) by imputation using the 1000 Genomes Project reference panel and identified 15 new loci associated with breast cancer.

The 1000 Genomes Project, launched in January 2008, is an international research effort to establish a detailed catalogue of human genetic variation. The project unites multidisciplinary research teams from institutes around the world, including China, Italy, Japan, Kenya, Nigeria, Peru, the United Kingdom, and the United States. Each team contributes to the enormous sequence dataset and to a refined human genome map, which is freely accessible through public databases to the scientific community and the general public alike. By providing an overview of all human genetic variation, not only what is already known to be bio-medically relevant, the consortium generates a valuable tool for all fields of biological science, especially in the disciplines of genetics, medicine, pharmacology, biochemistry, and bioinformatics.

Senior author Dr. Doug Easton, professor of public health and primary care at the University of Cambridge, said, “Our study is another step towards untangling the breast cancer puzzle. As well as giving us more information about how and why a higher breast cancer risk can be inherited, the genetic markers we found can help us to target screening and cancer prevention measures at those women who need them the most. The next bit of solving the puzzle involves research to understand more about how genetic variations work to increase a woman’s risk. And we are sure there are more of these variations still to be discovered.”

The study was published in the March 9, 2015, online edition of the journal Nature Genetics.

Related Links:

University of Cambridge


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.